Navigation Links
Purse String Clamp

ProductsPurse String Clamp
Company Ethicon, Inc.
Item Purse String Clamp
Features 
  • Reusable.
  • Intended for use in the mechanical construction of a purse string suture.
  • Can be used on any part of the gastrointestinal tract except the esophagus.
    • Description The Reusable Purse String Clamp is intended for use in the mechanical construction of a purse string suture. The clamp can be used on any part of the gastrointestinal tract except the esophagus.
    Info Ethicon, Inc.
    Customer Service: (800) 4-ETHICON
    Web site: http://www.ethicon.com/

    Related medicine products :

    1. Berens Muscle Clamp
    2. Berke Ptosis Clamp
    3. Desmarres Chalazion Clamps
    4. Mayfield 2000 Skull Clamp
    5. Mayfield Radiolucent Skull Clamp
    6. Modified Mayfield Skull Clamp
    7. Doro Skull Clamp
    8. Yasargil Spring Hool with Bulldog Clamp
    9. Vascular Clamps B-1
    10. Vascular Clamps B-2
    11. Vascular Clamps B-3
    The collection features a range of 18 Ophthalmic frames created with the most modern materials and producted to the very hightest quality. The Optical collection includes several super lightweight Ti
    The collection features a variety of colors and classic shapes, plus an array of feminine styles designed with elegant jewel detail. With styles for both men and women that are made from the same hig
    ...as put together a remarkable sunwear collection, a...ombines all of the benefits of the Titan Minimal A...th top quality sun lenses that offer 100% UV A, B ...comfortable, lightweight sun protection short of s...
    ...look of the collection has an urban twist with fas... plastic colors and rich metal tones. Design detai...enneth Cole Reaction apparel and accessory lines. ...ned with subtle top to bottom, dual-tone combinati...
    Medicine Products:
    (Date:5/11/2008)...ousands across the Country on Hand for Unveiling o...t Breast Cancer Organization, CHICAGO, May 11 /PR...,Day in 15 cities across the country were present ...nation,s oldest non-profit breast cancer,organizat...ization(TM) commemorates,its 30th anniversary. In ...
    (Date:5/10/2008)... MINNEAPOLIS, May 10 /PRNewswire/ -- The American ...ies to the survivors of the tragedy in,Myanmar. In...ife-saving,medical supplies and food, including it... and mosquito nets to thousands of survivors., AR...week, pending,visas. The team will be led by ARC T...
    (Date:5/9/2008)...nfirms popular whole grain may provide protection ... certain cancers, ARLINGTON, Va., May 8 /PRNewswi... joins the recognized ranks of healthful whole gra...he U.S. Food and Drug Administration,(FDA) that wi...grain health,claim. This will enable consumers to ...
    (Date:5/9/2008)... LOS ANGELES, May 9 /PRNewswire/ -- Los Angeles ba...oned in Asia to assess the needs of what is now,an... cyclone which,destroyed or devastated wide swaths...gon (formerly the capital Rangoon) and throughout ... winds of over 120 miles per hour and,struck commu...
    Breaking Medicine News(10 mins):Health News:Y-ME Makes Historic Announcement on Mother's Day 2Health News:Y-ME Makes Historic Announcement on Mother's Day 3Health News:FDA Approves Health Claim for Brown Rice 2Health News:FDA Approves Health Claim for Brown Rice 3Health News:FDA Approves Health Claim for Brown Rice 4Health News:FDA Approves Health Claim for Brown Rice 5Health News:Los Angeles Based Operation USA Appeals for Funds to Aid in Myanmar (Burmese) Cyclone Disaster (Updated) 2
    ...ity has made considerable progress. In five years ...dult stem cells, says Dr.Karim Nayerina, noted Ira... Nayernia, a professor of stem biology at the Uni...ted that he and his team had successfully coaxed t...
    ...d with tuberculosis in the Chambal region of Madhy...ies because they get no other jobs, constant expos...of getting TB. Saharia tribals and backward class...losis, dominate the Pahargarh, Chhaina, Likhiganj ...
    ...favour of a ban on smoking in workplaces and indoo...8 percent of citizens in the European Union want s...aces, said a study by the European Commission, the... EU health chief Markos Kyprianou said the broad s...
    ...ignificantly more likely to have persistent or sev...arts. The study was conducted by a team of resea...Hospital in Atlanta. As part of the study, resear...e National Asthma Survey, which includes 5,741 ast...
    Other Medicine News:Health News:Stem Cell Answer to Infertility in Five Years, Says Scientist 2Health News:Miners in Madhya Pradesh at High Risk of Developing TB 2Health News:Obese People More Prone to Severe Persistent Asthma 2
    (Date:5/8/2008)...Annual Meeting of the American Pain Society ... 8 /- Patients treated with lacosamid... neuropathic pain (DNP),compared to placebo-treat...th annual meeting of the American Pain Society (AP...trolled trial of a diabetic neuropathic,pain treat...
    (Date:5/8/2008)...Newswire-FirstCall/ -- AstraZeneca (NYSE:,AZN) tod...Drug Application,(sNDA) to the U.S. Food and Drug ...ne fumarate) Extended-Release Tablets to seek appr...rder (GAD), including maintenance of,antianxiety e...ht for an,atypical antipsychotic medicine in GAD. ...
    (Date:5/7/2008)...e Efficacy and Safety in Treating a Leading ...N, Germany, MONTVILLE, New Jersey and TARRYTOWN, N...lthCare AG and Regeneron,Pharmaceuticals, Inc. (NA...nt,has been dosed in the VIEW 2 trial, a second Ph...uating VEGF Trap-Eye for the treatment of the,neov...
    (Date:5/7/2008)...re-FirstCall/ -- Shire plc (LSE: SHP,Nasdaq: SHPG..., today,announced findings from a new data analysi...ces with DAYTRANA(TM) (methylphenidate transdermal... with Attention Deficit,Hyperactivity Disorder (AD...t DAYTRANA has an established safety profile and e...
    Breaking Medicine Technology:New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 2Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 3Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 4Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 5Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Pharsight to Host European Software Conference 1952 1Pharsight to Host European Software Conference 1952 2Health Organizations Join Forces Around Quit Smoking Help 1947 1Health Organizations Join Forces Around Quit Smoking Help 1947 2People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 1944 1People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 1944 2People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 1944 3People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 1944 4GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 1GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 2GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 3
    ...--Mar 26, 2007 - Pfizer announced today,that Lipit...d a,significant 61 percent reduction in stroke in ...me but without heart disease. In a,separate study,...ini-stroke during the trial had a significant 53 p...nts (death from cardiac causes,heart attack, or r...
    ... with statins for only five weeks at,400 mg/week l...tatins alone, with similarly favorable effects on ..., Calif., March 26, 2007,/PRNewswire-FirstCall/ --...from its Phase 2 clinical trial of ISIS 301012,coa... Cardiology,Annual Scientific Session (ACC) in New...
    Other Medicine Technology:Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 2Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 3Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 4Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9